-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Persistent hypertension may be a sodium retention state caused by abnormal aldehyde ketone secretion.
recently, a study published in JAHA, an authoritative journal in the field of cardiovascular disease, was a secondary analysis of the trial of aldosterone antagonists for the treatment of normal heart function heart failure (TOPCAT), which included patients with normal blood failure (HFpEF) with (n-1004) and non-persistent hypertension (n-2437).
Transcal hypertension is defined as hypertension in patients with systolic blood pressure ≥130mmHg and/or diastolic pressure ≥80mmHg) despite the simultaneous use of renin-angiotensin system blockers (angiotensin conversion enzyme inhibitors/angiotensin blockers) calcium channel blockers and diuretics≥
the study was a complex outcome of cardiovascular death, cardiac arrest or hospitalization for heart failure.
researchers analyzed the risk ratio (HRs) of 95% CI in the in-screw ester group using the Cox proportional risk model and compared it to the placebo group.
the risk of major outcome events in patients with persistent hypertension associated with intransigent hypertension was significantly lower than in the placebo group (HR 0.70; 95% CI was 0.53-0.91; P=0.009), while in patients with HFpEF without persistent hypertension, there was no significant difference between the two groups of major outcome event risk (HR was 1.00); 95% CI is 0.83-1.20;
there is a significant interaction between the use of intra-screw esters and stubborn hypertension (P-0.03).
, it can be seen that intrasterester may be an effective drug for treating HFpEF patients with persistent hypertension.
。